Palladyne AI Corp. (PDYN)
NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-09-09
$5.75-0.52%
Close 2026-09-09 · 1-day change
NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-09-09
Broken: Primary pillar broken — Free cash flow improves to about $2 million in FY25: FCF guidance $1.6M-$2.0M vs ~$2M target.
Palladyne aims to grow revenue to about $25.5 million in 2026. It has a strong partnership with Israel Aerospace Industries. The company plans to improve cash flow and net income. These steps could help it become profitable.
Palladyne lost $12.6 million in net income in early 2026. Cash flow is negative and getting worse. Revenue is expected to shrink by 7% next year. These problems could continue or get worse.
The price is about 34% below our fair value near $8. Analysts expect revenue to fall about 7%. Our fair value is below the Street median of $11.
Breaks if: Free cash flow remains negative or below $1.6 million in FY25
Breaks if: Net loss worsens beyond -$12.6 million in next 4 quarters
Partnership stalls or reverses in next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment with a focus on the technology sector. The current thesis state is mixed, as the company is navigating through recent earnings misses while attempting to execute on growth initiatives.
The market seems to be pricing in a high level of fragility due to the company's expensive valuation, despite its weak financial performance. There is an expectations gap indicating that the market may not fully account for the challenges PDYN faces.
Fundamentals are likely to remain under pressure in the near term due to a 40% probability of missing earnings expectations. However, management's focus on revenue growth and cash burn management shows some positive signs for the multi-year thesis.
The thesis hinges on key factors such as the potential for favorable macroeconomic conditions, like Fed rate cuts, and performance of sector leaders that could influence PDYN's momentum. Additionally, management's ability to execute on their growth priorities will be crucial.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company faces challenges in achieving its full-year revenue guidance of $24 million to $27 million. Revenue growth is positive, but widening operating losses raise concerns.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Execute exclusive U.S. rights partnership to manufacture and market IAI loitering munitions to the U.S. Department of War, adapting systems for U.S. requirements and scaling manufacturing.
Stated as a priority in 2 recent disclosures including 2026-Q2. The partnership with Israel Aerospace Industries grants Palladyne exclusive U.S. rights to manufacture and market combat-proven loitering munitions. This strategic move aligns with management's emphasis on expanding defense capabilities and is supported by the June 2026 announcement and the Q2 2026 report. The trajectory shows active execution of this partnership as a core growth initiative.
“Signed partnership with Israel Aerospace Industries (IAI) during the quarter, exclusive U.S. rights to manufacture and market IAI loitering munitions.”
Breaks if: Revenue falls below $24 million in FY26
Execute exclusive U.S. rights partnership to manufacture and market IAI loitering munitions to the U.S. Department of War, adapting systems for U.S. requirements and scaling manufacturing.
Stated as a priority in 2 recent disclosures including 2026-Q2. The partnership with Israel Aerospace Industries grants Palladyne exclusive U.S. rights to manufacture and market combat-proven loitering munitions. This strategic move aligns with management's emphasis on expanding defense capabilities and is supported by the June 2026 announcement and the Q2 2026 report. The trajectory shows active execution of this partnership as a core growth initiative.
“Signed partnership with Israel Aerospace Industries (IAI) during the quarter, exclusive U.S. rights to manufacture and market IAI loitering munitions.”
Over the next 1 to 3 years, PDYN's outlook remains uncertain, with significant risks and challenges ahead. Not investment advice.